Related Experiment Video
Updated: Oct 5, 2025
06:22
Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models
Published on: February 2, 2024
4.0K
Roadmap to affinity-tuned antibodies for enhanced chimeric antigen receptor T cell function and selectivity
Erica R Vander Mause1, Djordje Atanackovic2, Carol S Lim3
1Department of Microbiology and Immunology, University of Maryland, Baltimore, MD 21201, USA; Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, UT 84112, USA; A2 Biotherapeutics, Agoura Hills, CA, 91301, USA.
Trends in Biotechnology
|January 26, 2022
Summary
Low-affinity CAR T-cell binders enhance cancer therapy by improving T-cell persistence and tumor cell selectivity. This review explores engineering low-affinity binders for more effective CAR T-cell treatments.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Chimeric antigen receptor (CAR) T cells are a revolutionary cancer therapy.
- Current CAR T cells utilize high-affinity binders, leading to limited persistence and off-target effects.
Purpose of the Study:
- To review the use of low-affinity CAR-binding domains in cancer therapy.
- To evaluate technologies for engineering and screening low-affinity antibody variants.
- To propose a workflow for developing optimal low-affinity binders.
Main Methods:
- Review of recent scientific literature on CAR T-cell therapy.
- Evaluation of technologies for antibody engineering and screening.
- Proposal of a streamlined development workflow.
Main Results:
- High-affinity binders cause excessive T-cell activation, limiting efficacy.
- Low-affinity binders offer improved T-cell persistence and tumor selectivity.
- Various technologies exist for engineering and screening low-affinity antibody variants.
Conclusions:
- Low-affinity CAR-binding domains represent a promising strategy to enhance CAR T-cell therapy.
- Optimized low-affinity binders can lead to more functional and selective cancer therapeutics.
- A standardized workflow is needed to accelerate the development of these improved CAR T cells.
